HMGB-1 as a useful prognostic biomarker in sepsis-induced organ failure in patients undergoing PMX-DHP

Journal of Surgical Research

Volumn 171, Issue 1, 2011, Pages 183-190

  Ueno, Takuya ^a   Ikeda, Toshiaki ^a   Ikeda, Kazumi ^a   Taniuchi, Hitoshi ^a   Suda, Shingo ^a   Yeung, Melissa Y ^b   Matsuno, Naoto ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

HMGB 1; multi organ failure; PMX DHP; septic marker; septic shock; SOFA

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; POLYMYXIN B;

ADULT; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HEMODYNAMIC MONITORING; HEMOPERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SEPTIC SHOCK; SURVIVAL;

AGED; ANTI-BACTERIAL AGENTS; APACHE; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; HEMOPERFUSION; HMGB1 PROTEIN; HUMANS; INTERLEUKIN-6; LIVER FAILURE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC;

EID: 80054704092     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2009.11.708     Document Type: Article

References (43)

1. S.M. Hollenberg Vasopressor support in septic shock Chest 132 2007 1678
2. H. Shoji Extracorporeal endotoxin removal for the treatment of sepsis: Endotoxin adsorption cartridge (Toraymyxin) Ther Apher Dial 7 2003 108
3. R.P. Dellinger, J.M. Carlet, and H. Masur Surviving sepsis campaign guidelines for management of severe sepsis and septic shock Intensive Care Med 30 2004 536
4. H. Kushi, T. Miki, and J. Nakahara Hemoperfusion with an immobilized polymyxin B column reduces the blood level of neutrophil elastase Blood Purif 24 2006 212
5. H. Kushi, T. Miki, and K. Okamaoto Early hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation Crit Care 9 2005 R653
6. Y. Sakamoto, K. Mashiko, and T. Obata Clinical responses and improvement of some laboratory parameters following polymyxin B-immobilized fiber treatment in septic shock Asaio J 53 2007 646
7. T. Ueno, M. Sugino, and H. Nemoto Effect over time of endotoxin adsorption therapy in sepsis Ther Apher Dial 9 2005 128
8. J.L. Vincent, P.F. Laterre, and J. Cohen pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection Shock 23 2005 400
9. D.N. Cruz, M.A. Perazella, and R. Bellomo Effectiveness of polymyxin B-immobilized fiber column in sepsis: A systematic review Crit Care 11 2007 R47
10. S.M. Opal, and T. Gluck Endotoxin as a drug target Critical Care Med 31 2003 S57
11. B. Uzzan, R. Cohen, and P. Nicolas Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: A systematic review and meta-analysis Crit Care Med 34 2006 1996
12. A.L. Van Dervort, and R.L. Danner Antiendotoxin approaches to septic shock therapy Critical Care Med 22 1994 539
13. H. Wang, O. Bloom, and M. Zhang HMG-1 as a late mediator of endotoxin lethality in mice Science 285 1999 248
14. G.W. Waterer High-mobility group box 1 (HMGB1) as a potential therapeutic target in sepsis-More questions than answers Critical Care Med 35 2007 1205
15. L.L. Mantell, W.R. Parrish, and L. Ulloa Hmgb-1 as a therapeutic target for infectious and inflammatory disorders Shock 25 2006 4
16. S. Gibot, F. Massin, and A. Cravoisy High-mobility group box 1 protein plasma concentrations during septic shock Intensive Care Med 33 2007 1347
17. T. Hatada, H. Wada, and T. Nobori Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation Thromb Haemost 94 2005 975
18. S. Karlsson, V. Pettila, and J. Tenhunen HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis Intensive Care Med 34 2008 1046
19. R.C. Bone, R.A. Balk, and F.B. Cerra Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Chest 101 1992 1644
20. A. Kumar, D. Roberts, and K.E. Wood Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock Critical Care Med 34 2006 1589
21. M. Shikano, H. Sobajima, and H. Yoshikawa Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy Nephron 85 2000 81
22. S. Yamada, K. Yakabe, and J. Ishii New high mobility group box 1 assay system Clin Chim Acta 372 2006 173
23. T. Ikeda, K. Ikeda, and M. Nagura Clinical evaluation of PMX-DHP for hypercytokinemia caused by septic multiple organ failure Ther Apher Dial 8 2004 293
24. K.J. Tracey Physiology and immunology of the cholinergic anti-inflammatory pathway J Clin Invest 117 2007 289
25. Y. Tateishi, S. Oda, and M. Nakamura Depressed heart rate variability is associated with high IL-6 blood level and decline in the blood pressure in septic patients Shock 28 2007 549
26. H. Hirasawa, S. Oda, and K. Matsuda Continuous hemodiafiltration with cytokine-adsorbing hemofilter in the treatment of severe sepsis and septic shock Contrib Nephrol 156 2007 365
27. T. Ikeda Hemoadsorption in critical care Ther Apher 6 2002 189
28. K. Matsuda, H. Hirasawa, and S. Oda [Endotoxin removal in septic shock] Nippon Geka Gakkai Zasshi 103 2002 880
29. T. Shimizu, K. Hanasawa, and K. Sato Direct hemoperfusion with polymyxin-B-immobilized fiber columns improves septic hypotension and reduces inflammatory mediators in septic patients with colorectal perforation Langenbecks Arch Surg 394 2009 303
30. T. Tojimbara, S. Sato, and I. Nakajima Polymyxin B-immobilized fiber hemoperfusion after emergency surgery in patients with chronic renal failure Ther Apher Dial 8 2004 286
31. N.C. Riedemann, R.F. Guo, and P.A. Ward Novel strategies for the treatment of sepsis Nat Med 9 2003 517
32. L. Ulloa, and K.J. Tracey The "cytokine profile": A code for sepsis Trends Mol Med 11 2005 56
33. U. Anderson, H. Wang, and K. Palmblad High mobility group 1 protein (HMG-1) stimulates pro-inflammatory cytokine synthesis in human monocytes J Exp Med 192 2000 565
34. S. Ivanov, A.M. Dragoi, and X. Wang A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA Blood 110 2007 1970
35. J. Tian, A.M. Avalos, and S.Y. Mao Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE Nat Immunol 8 2007 487
36. M. Andrassy, H.C. Volz, and J.C. Igwe High-mobility group box-1 in ischemia-reperfusion injury of the heart Circulation 117 2008 3216
37. M. Ilmakunnas, E.M. Tukiainen, and A. Rouhiainen High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation Liver Transpl 14 2008 1517
38. A. Tsung, R. Sahai, and H. Tanaka The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion J Exp Med 201 2005 1135
39. T. Watanabe, S. Kubota, and M. Nagaya The role of HMGB-1 on the development of necrosis during hepatic ischemia and hepatic ischemia/reperfusion injury in mice J Surg Res 124 2005 59
40. M.H. Hussein, T. Kato, and T. Sugiura Effect of hemoperfusion using polymyxin B-immobilized fiber on IL-6, HMGB-1, and IFN gamma in a neonatal sepsis model Pediatr Res 58 2005 309
41. Y. Sakamoto, K. Mashiko, and H. Matsumoto Relationship between effect of polymyxin B-immobilized fiber and high-mobility group box-1 protein in septic shock patients Asaio J 53 2007 324
42. M. Pahuja, C. Tran, and H. Wang Alveolar macrophage suppression in sepsis is associated with high mobility group box 1 transmigration Shock 29 2008 754
43. M.A. van Zoelen, H. Yang, and S. Florquin Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo Shock 31 2009 280